Carcinogen Hazard Assessment Monographs Program (CHAMP) (R01 Clinical Trial Not Allowed)
Agency
National Institutes of Health
Posted
Oct 9, 2026
Due Date
Feb 9, 2027
Description
<p>Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute invites applications to the <i>Carcinogen Hazard Assessment Monographs Program (CHAMP) </i>Initiative<i>. </i>NCI seeks meritorious proposals to critically and systematically evaluate the scientific evidence on carcinogenic hazards to humans. Identifying potential carcinogens is essential for guiding and advancing cancer research, as well as informing cancer control and prevention efforts. </p>
AI Summary
Estimated Funding: 800,000 | Award Ceiling: 700,000 | Agency: National Institutes of Health
Details
- Notice ID
- 360905
- Solicitation Number
- RFA-CA-28-013
- Classification Code
- D
Want to track opportunities like this?
Sign up for Kontratar to get AI-powered opportunity matching, ranking, and alerts.
Get Started FreeRelated opportunities
- NextTech: Translational Development of Next-Generation Diagnostic and Therapeutic Devices (R18 Clinical Trial Not Allowed)
National Institutes of Health
- CAPSTONE Centers for Multidisciplinary Research in Child Abuse and Neglect
National Institutes of Health
- Prevention and Treatment through a Comprehensive Care Continuum for HIV-affected Adolescents in Resource-Constrained Settings--Implementation Science Network (PATC3H-IN)
National Institutes of Health
- Discovery Gateway to Reproductive Health Innovation
National Institutes of Health
- National Resource Network for the Study of Human Auditory and Vestibular Disorders (U24 Clinical Trial Not Allowed)
National Institutes of Health
- Coordinating Center for National Resource Network for the Study of Human Auditory and Vestibular Disorders (U24 Clinical Trial Not Allowed)
National Institutes of Health
- Immune Tolerance Network (UM1 Clinical Trial Required)
National Institutes of Health
- Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinical Trial Not Allowed)
National Institutes of Health